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   The 22nd Scientific Conference on the Biology of Vitamin D (aka the Vitamin D Workshop) was 
held in the Crowne Plaza Hotel in New York City from May 29-June 1, 2019.  The workshop was 
organized by Dr. James Fleet (Chair, Purdue University, USA), Dr. JoEllen Welsh  (Chief 
Financial Officer of the Vitamin D Workshop, Inc, SUNY Albany, USA), and Roxanne Hall  
(Meetings Plus).   Topical sessions and speakers were chosen by the Vitamin D Workshop 
Executive Committee with input from the Program Advisory Committee 
(https://vitamindworkshop.org/about).  The meeting attracted 262 delegates from around the 
globe.  During the meeting, there were 42 podium presentations (16 invited speakers, 26 
promoted abstracts) and 124 poster presentations.   The meeting began on the evening of May 
28 with an opening reception and 24 Plenary Poster presentations.  The following two and a half 
days of meetings were organized into 13 sessions covering topics in basic science, clinical 
research, epidemiology, and policy.   Flash poster sessions were held on May 30 and May 31 
prior to an open poster session that was held concurrent with lunch.  Delegates who presented 
primary research studies or invited presentations were invited to submit a manuscript for peer 
reviewed publication in this special edition of the Journal of Steroid Biochemistry and Molecular 
Biology.   Each submitted manuscript was peer reviewed according to Journal standards.  Guest 
editors for the special issue were: Dr. James Fleet, Dr. Paul Anderson (University of South 
Australia), and Dr. Peter Ebeling (Monash University, Australia).  Summaries of all oral 
sessions are presented below.    
 
The first day of the meeting started with opening remarks by the Chair, Dr. James Fleet.   This 
was followed by Session I , a keynote lecture on The Year in Vitamin D: Basic Research  
presented by Dr. Carlos Bernal-Mizrachi (Washington University, USA).  This session was 
chaired by Dr. JoEllen Welsh (SUNY Albany, USA). Dr. Bernal-Mizrachi provided an excellent 
overview of some of the key publications within the vitamin D field from 2018 and 2019, focusing 
on basic science research discoveries regarding vitamin D metabolism and its consequences. 
He first discussed two novel genetic forms of vitamin D deficiency. One publication described 
two patients with early-onset rickets due to heterozygous point mutations in CYP3A4, resulting 
in 10-fold higher enzyme activity and accelerated catabolism of vitamin D metabolites [1].  The 
second publication described a case of a middle-aged woman with debilitating ankylosing 
spondylitis with severe vitamin D deficiency that did not respond to supplementation because of 
to a homozygous deletion of the group-specific component (GC) of the vitamin D binding protein 
[2]. This patient, despite a lifelong deficiency of vitamin D–binding protein, did not have rickets 
or osteomalacia but rather mild bone disease.  This suggests that cholecalciferol is locally 
hydroxylated to form the active, vitamin D hormone, which can then prevent adverse 
consequences of serum vitamin D deficiency. 
Next, Dr. Bernal-Mizrachi described the discovery that environmental conditions such as 
prolonged food deprivation in mice can repress hepatic CYP2R1 expression and vitamin D 25-
hydroxylation via marked activation of hepatic PGC1α-ERRα and glucocorticoid receptor [3]. 
Additional data suggested that repression of hepatic CYP2R1 occurs in high-fat-diet-induced 
obesity, with insulin resistance, and in type 1 diabetes models, suggesting that the high 
prevalence of vitamin D deficiency occurring with these disease states could be secondary to 
prolonged hepatic energy deprivation. It is unclear whether vitamin D plays a role in either beta 
cell failure or tissue insulin action. Dr. Bernal-Mizrachi also discussed research that showed how 
the vitamin D receptor (VDR), by modulating islet stress, can have a protective role in beta cell 
survival [4]. This publication reported that VDR activation changes chromatin accessibility at 
consensus VDR binding elements and that this then suppresses expression of critical 
inflammatory genes and improves beta cell function and survival.  Moreover, other research 
shows that VDR activation promotes insulin exocytosis from the beta cell under high-glucose 
conditions via increased expression of a voltage-gated calcium channel [5]. In diet-induced 
obesity and insulin resistance, intraperitoneal administration of active vitamin D reduces body 
weight and improves muscle myosteatosis and insulin resistance by decreasing activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and by lowering tumor 
necrosis factor alpha (TNFα) level [6]. Interestingly, the knockout of the VDR gene also protected 
mice from diet-induced obesity, high serum triglycerides, fatty liver, and adipose inflammation [7]. 
These changes in lipid metabolism were partially reversed by intestine-specific Vdr 
overexpression, which increased intestinal luminal lipase.  This suggests a new role for intestinal 
Vdr on systemic lipid homeostasis. Other publications addressed additional roles for gut VDR 
signaling in mice. Colonic-specific deletion of epithelial Vdr aggravates epithelial cell apoptosis, 
resulting in increased mucosal barrier permeability, luminal bacterial invasion, and dendritic cell 
activation of mucosal Th1 and Th17 responses [8]. Dr. Bernal-Mizrachi also described research 
on how the intestinal clock system affects VDR and regulates skeletal bone homeostasis [9]. 
Clock proteins bind to cell-specific enhancers and drive rhythmic expression of target genes. Mice 
lacking intestinal clock proteins have loss of rhythmic expression of intestinal VDR target genes 
with a resultant reduction in calcium absorption that contributes to bone loss. Research describing 
a novel mechanisms of bone fracture repair in mice with knockout of the CYP24 enzyme was also 
discussed [10]. In this work, the authors demonstrated that lactosylceramide generated by the 
interaction of 24R,25(OH)2D3 with the transmembrane protein FAM57B2 is essential for 
endochondral ossification and strong callus formation after fracture. Conversely, 1,25(OH)2D 
treatment suppresses the osteogenic functions of pro-inflammatory M1 macrophages  and this 
ultimately reduces mesenchymal stem cell abundance and impairs fracture repair [11].  Thus, this 
research suggests that 1,25(OH)2D treatment may be detrimental during fracture healing. Finally, 
Dr. Bernal-Mizrachi discussed research that showed Vitamin D exerts an anti-inflammatory effect 
in the pathogenesis of psoriasis [12]. In an experimental mouse model of psoriasis, activation of 
skin VDR with topical calcipotriol suppressed IL-36α/γ and IL-23/IL-17 expression and inhibited 
neutrophil infiltration into skin lesions. 
    The topic of Session II was Vitamin D receptor – Transcription/Mechanism of Act ion  and 
it was chaired by Dr. Sylvia Christakos (Rutgers New Jersey Medical School, USA).  This 
session started with an invited lecture by Dr. Moray Campbell (Ohio State University, USA) 
who talked about the opportunities, challenges, and future prospects for the use of genomics 
approaches in vitamin D research.  By alternating between a “20,000 ft” view and a “2000 ft” 
view, Dr. Campbell explained how genomic approaches can illuminate our understanding of 
vitamin D action through the vitamin D receptor (VDR) as well as how these regulatory events 
can relate to human health and disease. In the short talk that followed, Dr. Takashi Ishii (Ulster 
University, Ireland) reported how protein inhibitor of activated STAT4 (PIAS4)-mediated 
SUMOylation of the VDR could alter vitamin D transcriptional activity.  They reported that 
SUMOylation represses VDR transcriptional activity at least in part by altering chromatin 
structure and VDR-coregulator interactions.  Next, Dr. Seong Min Lee (University of Wisconsin, 
USA) reported the results of studies that used genetically modified mice to study the 1,25(OH)2 
D-mediated regulation of the Fgf23 gene, a critical step in the regulation of whole body 
phosphate metabolism.  He demonstrated that 1,25(OH)2 D uses a novel upsteam enhancer 
region to regulate Fgf23 gene expression.  In contrast, dietary phosphate restriction-mediated 
regulation of Fgf23 is more complex and does not rely on the vitamin D regulated upstream 
enhancer or several other putative regulators they tested.  In the last talk in this session, Dr. 
John White (McGill University, Canada) reported a novel reanalysis of 80 published human 
transcript profiling studies that sought to provide a more clear understanding of the impact of 
vitamin D signaling on the genome.  This analysis highlighted the cell-specificity of vitamin D 
signaling.  In addition, it revealed that cells that are critical to the innate immune response were 
the richest source of vitamin D regulated genes.  Thus, this data integration analysis provided a 
powerful resource for future mechanistic studies on cell-specific and immune modulatory effects 
of vitamin D signaling.  
 
Session III  on Vitamin D Metabolism  was held in honor of Dr. Helen Henry, one of the 
pioneers of vitamin D metabolism who passed away in 2018. It was chaired by Dr Martin 
Hewison (University of Birmingham, UK) and was preceded by a tribute to Dr. Henry by Dr. Dan 
Bikle (University of California, San Francisco, USA).  Dr. Bikle presented an overview of Dr. 
Henry’s career achievements and her legacy to Vitamin D Workshop, thus providing a moving 
introduction to the area of vitamin D research she was most closely associated with. The 
session proper began with a talk by Dr. Mark Myer  (University of Wisconsin, USA) describing 
the latest advances in our understanding of the molecular basis for regulation of serum 
1,25(OH)2D3 levels [13]. Dr Meyer described mouse models that have been used to dissect the 
coordinated, reciprocal expression and activity of the enzymes vitamin D-1α-hydroxylase 
(Cyp27b1) and 24-hydroxylase (Cyp24a1). In particular, these studies identified kidney-specific 
enhancer modules within introns of the Metl1 and Metl21b genes that mediated basal, 
parathyroid hormone (PTH)-induced, and fibroblast growth factor 23 (FGF23)-suppressed 
Cyp27b1 expression. Deletion of both of the intronic enhancer modules completely ablated 
renal synthesis of 1,25(OH)2D3 but had no effect on extra-renal synthesis. Enhancer module 
knockout also decreased levels of 24,25(OH)2D3 indirectly as a consequence of elevated PTH 
and suppressed FGF23.  Meanwhile, direct regulation of Cyp24a1 by PTH and FGF23 involved 
a set of downstream enhancers that were distinct from the Metl1/Metl21b intronic enhancers 
observed for Cyp27b1. These data, and related human studies, underline the exquisite 
molecular regulatory mechanism involved in controlling circulating levels of 1,25(OH)2D3.  
The second talk in Session III by Dr Jane Cleal  (University of Southampton, UK) described 
studies of the uptake and metabolism of vitamin D in the placenta. Experiments were carried out 
using villous fragments of fresh human term placentas incubated with C13-labeled 25 
hydroxyvitamin D3 (25OHD3) in a perfusion system. The resulting data indicated that 25OHD3 
was taken up by the placenta via a blockable endocytic mechanism, and then converted to 
24,25(OH)2D3 and 1,25(OH)2D3. These vitamin D metabolites were then able to pass into the 
maternal and fetal circulation systems. Through this mechanism, enhanced serum 25OHD3 was 
able to regulate the expression of 493 genes and 246 proteins, notably including the 
suppression of inflammatory pathways. These data further underline the importance of maternal 
25OHD3 levels in maintaining optimal placental function and, in turn, healthy fetal development. 
In a separate but related study, Dr JoEllen Welsh  (University of Albany, USA) used wild type 
(WT) and vitamin D binding protein (DBP) knockout mice to assess levels of vitamin D3, and 
25OHD3 in the liver and breast tissues. Data indicated that in the vitamin D forms accumulate in 
both tissues but with higher accumulation in mammary glands of the DBP knockout mouse. 
Also, DBP was not required for release of vitamin D3 or 25OHD3 from mammary tissue. These 
data show that uptake of vitamin D metabolites is a crucial factor in target tissue responses to 
vitamin D. In the final presentation of Session III, Dr Martin Kaufmann (Queens University, 
Canada) presented data showing that the ratio of 25OHD3 to 24,25(OH)2D3 is a better marker of 
renal vitamin D metabolism than simple measurement of 25OHD3.  Using a cohort of chronic 
kidney disease (CKD) dialysis patients and non-dialysis CKD patients, liquid chromatography-
tandem mass spectrometry analysis of vitamin D metabolites showed that suppressed renal 1α-
hydroxylase and 24-hydroxylase activities in the dialysis patients dramatically decreased serum 
levels of 1,25(OH)2D3 but also increased the ratio of 25OHD3 to 24,25(OH)2D3. These data 
suggest that, similar to what has been reported in subjects with CYP24A1 gene mutations, 
measurement of the ratio of 25OHD3 to 24,25(OH)2D3 may be a meaningful measure of vitamin 
D metabolism and function in patients with kidney disease.  
 
Session IV  was moderated by Dr. James Fleet (Purdue University, USA) and Dr. Roger 
Bouillon (KU Leuven, Belgium).  The goal of this session was to provide an update on several 
large Vitamin D Clinical Trials that were recently completed or will be complete in the near 
future. These studies were the Vitamin D Assessment (ViDA) Study (presented by Dr. Robert 
Scragg, University of Auckland, NZ), the Vitamin D and Omega-3 (VITAL) study (presented by 
Dr. JoAnn Manson, Harvard University, USA), and the Vitamin D and Type 2 Diabetes (D2D) 
Study (presented by Dr. Anastassios Pittas, Tufts University, USA).  Each presenter reviewed 
the goals and design of their study.  The primary goals of the ViDA trial were to assess the 
effect of monthly vitamin D3 supplementation (100,000 IU) on non-skeletal diseases (i.e. 
cardiovascular disease, cancer, mortality) in adults from New Zealand.  The VITAL study 
examined the impact of daily vitamin D3 (2000 IU) and/or omega-3 fatty acid (1 g) on total 
invasive cancer and major cardiovascular events in US adults. These two trial are complete and 
summaries of these presentations are available in this special issue [14, 15]. The D2D 
examined whether daily vitamin D3 (4000 IU) could reduce the risk of diabetes in adults at high 
risk for diabetes. Unfortunately, the results of the D2D trial were embargoed prior to their 
publication in June 2019 [16] so Dr Pittas was only able to discuss the study design and 
research goals.  In addition to the reporting of the results of ViDA and VITAL, all three 
presenters participated in a lively discussion on the challenges faced during large vitamin D 
supplementation trials.   These challenges included issues such as: the lack of pre-study vitamin 
D status levels, the cost-prohibitive nature of measuring serum 25OHD in all subjects, the 
inclusion of both vitamin D insufficient and vitamin D replete subjects in the trial, the high use of 
vitamin D supplement use in the study populations, the high cost of conducting trials with 
multiple doses of vitamin D, the expectation that intervention studies will be analyzed based on 
“intent to treat” despite the use of out-of-study vitamin D supplements by subjects or the level of 
subject compliance, and the existence of latent disease in the study population at the trial 
outset.   There was also some discussion of the value that alternative analyses of the data have 
for interpreting the importance for vitamin D in human health as well as how the media report 
the complexities of study results. 
 
The last session of the first day, Session V: Eradication of rickets,  was chaired by Dr Rolf 
Jorde (UiT The Arctic University of Norway). This session was at the request of Dr Roger 
Bouillon (KU Leuven, Belgium) who gave a brief overview of rickets and outlined how to 
convince the World Health Organization (WHO) to set up a plan to eradicate nutritional rickets 
before 2030. The reported prevalence of rickets varies considerably, from a few percent in some 
African countries to more than 50 % in Tibet and Mongolia [17]. The remedy for this is 
straightforward - vitamin D supplementation to infants and children - and there is no shortage of 
guidelines for such supplementation. At the Vitamin D workshop in Delft in 2015 a separate 
session was held with WHO representatives to discuss a potential eradication program for 
rickets, and at the International Congress of Endocrinology in Cape Town 2018 Dr. Bouillon 
received full support for an action plan to persuade WHO to implement such a program. This 
plan was presented in the present session and consists of the following steps: appointment of a 
task force on behalf of endocrine societies and Vitamin D workshop; convince leadership of 
WHO in Geneva; persuade member countries of WHO to ask WHO to implement an eradication 
plan; and get eradication of rickets on the agenda of the general assembly of WHO for approval. 
In the discussion following this presentation, there was unanimous support for this plan. The 
next step will be to establish the task force including a writing group for the WHO memorandum, 
and an advisory group to finalize this document.  
 
Session VI examined the role of Vitamin D in Cancer  and was chaired by Dr. Eniko Kallay 
(University of Vienna, Austria) and Dr. David Feldman (Stanford University, USA).   Dr. 
Leonard Augenlicht (Albert Einstein College of Medicine, USA) opened the session with an 
invited talk on how the vitamin D and nutritional environment influence intestinal stem cells in 
ways that contribute to tumorigenesis [18].  His lecture built upon his earlier work that showed 
high fat “western diets” low in calcium and vitamin D increase the incidence of intestinal cancers 
in mice.  In his lecture, Dr. Augenlicht reported that diet has an impact on the earliest stages of 
colon cancer through a complex interaction among stem-cell populations.  Specifically, the 
“western diet” reprograms the transcriptome of the Lgr5+ intestinal stem cell and reduces its 
contribution to normal intestinal tissue homeostasis.   As the same time, the “western diet” 
reprograms Bmi1+ cells to make them function and persist as stem-cells in both normal 
intestinal homeostasis and tumorigenesis. These data suggest that diets low in vitamin D are an 
avoidable and modifiable stress that contribute to colon cancer initiation.    
   Dr. Augenlicht’s lecture was followed by five short research presentations.  The first of these 
was by Dr. Pamela Hershberger (Roswell Park Cancer Center, USA), who examined the 
mechanism by which 1,25(OH)2D exerts a protective effect on EGFR tyrosine kinase inhibitor 
(TKI) resistant lung cancer.  By using multiple cell models of EGFR TKI resistance that undergo 
epithelial-mesenchymal-transition (EMT), she showed that 1,25(OH)2 D could enhance EGFR 
TKI-induced G0/G1 growth arrest and reverse the EMT phenotype of some models.  In addition, 
in a small clinical study, she showed that patients with higher serum 25OHD levels (>30 ng/ml) 
had a longer benefit from EGFR TKI inhibition than patients with low serum 25OHD levels.  This 
suggests vitamin D metabolites or analogs might be developed as adjunctive treatments for 
EGFR TKI therapy.    
   The second short talk in the session was by Dr. James Fleet (Purdue University, USA) who 
presented research on the impact that vitamin D signaling has on myeloid derived suppressor 
cells (MDSC), an immunosuppressive cell in the tumor microenvironment that promotes tumor 
growth.   He showed that tumor MDSC express that VDR and are vitamin D target cells.    
MDSC support tumor growth by suppressing proliferation of anti-tumor cytotoxic T cells.  Using 
both 1,25(OH)2D treatment and VDR deletion, Dr. Fleet showed that signaling through the VDR 
blocks the development this immunosuppressive function. He presented data to show that this 
is in part due to vitamin D mediated effects on traditional mediators of MDSC 
immunosuppressive function like ARG1 and NOS2.   Collectively, his data suggest that 
activation of vitamin D signaling could be used to suppress MDSC function and thereby 
enhance T-cell mediated immunotherapies.    
   The third short talk by Dr. Jason Garcia (University of Illinois-Chicago, USA) examined the 
role of megalin-mediated vitamin D uptake and its role in observed differences in intraprostatic 
androgens between African-American (AA) and Caucasian men.  This group had previously 
found that megalin is express in prostate epithelium and that the serum and prostate levels of 
vitamin D metabolites are correlated in AA men. Consistent with a role for megalin in prostate 
steroid hormone uptake, 25OHD bound to the vitamin D binding protein and testosterone bound 
to the sex hormone binding globulin were both imported into in primary prostate epithelial cells 
and human prostate tissue slices and both induced their respective hormone-driven gene 
expression.  25OHD also reduced expression of the megalin gene (LRP2) in these models.  In 
human subjects, dihydrotestosterone (DHT) levels were inversely correlated to serum 25OHD 
level and DHT levels were higher in AA men, who normally have low serum 25OHD levels.  This 
suggests that vitamin D deficiency could increase androgen import into the prostate through 
megalin.    
   In the fourth short talk, Aparajita Verma (Roswell Park Cancer Center, USA) reported on the 
impact of vitamin D signaling on immune checkpoint blockade (ICB) in head and neck (H&N) 
cancer.  She noted that immune checkpoint inhibitors that block binding of PD-L1 to the 
programmed cell death protein (PD-1) work in only a subgroup of H&N cancer patients.  
However, since 1,25(OH)2D increases intratumoral infiltration of CD4+ and CD8+ T cells in H&N 
cancer models and patients, they hypothesized that vitamin D signaling may regulate the PD-
1/PD-L1 axis in vivo.  Consistent with this hypothesis, 1,25(OH)2D induced PD-L1 mRNA and 
protein expression in a novel mouse H&N cancer model (RP-mSCC1 cells).  In mice with RP-
mSCC1 tumors, 1,25(OH)2D modestly reduced tumor growth but increased tumor CD4+ and 
CD8+ cells and PD-L1 levels.  However, 1,25(OH)2D also enhanced the anti-tumor effect of 
anti-PD-1 antibody immunotherapy.  This suggest 1,25(OH)2D might be an effective adjunct 
treatment to enhance ICB in humans. 
   The final talk of Session VI was by Dr. Alicia Heath (Imperial College London, UK).  She 
reported the results of a case-cohort study nested within the Melbourne Collaborative Cohort 
Study that examined the association between serum 25OHD and cause-specific mortality.  By 
using data on the 2307 participants who died during the 14 y follow-up, she found that 25OHD 
was inversely associated with the risk of cancer death, particularly colon cancer, but it wasn’t 
associated with the risk of death due to breast, lung, pancreatic, or prostate cancer. Higher 
serum 25OHD levels were also associated with lower risk of death due to respiratory system 
diseases and digestive system diseases but there was no evidence of an association with 
cardiovascular disease mortality. 
 
   The Session VII  topic Vitamin D and the Microbiome or Immunity was chaired by Dr. 
Margherita Cantorna (Pennsylvania State University, USA) and Dr. John White  (McGill 
University, Canada). The session began with two presentations on the effects of vitamin D on 
the microbiota.  Dr. Tangpricha (Emory University, USA) discussed the effects of a vitamin D 
intervention on the microbiome in patients with cystic fibrosis [19]. The double blind, placebo-
controlled randomized clinical trial recruited patients with low vitamin D status (25(OH)D <30 
ng/mL) and used either a 50,000 IU vitamin D/week or placebo for 12 weeks. A third group of 
cystic fibrosis patients with 25OHD levels over 30 ng/mL served as an additional control group. 
The vitamin D intervention improved 25OHD levels in the supplemented group compared to 
placebo. In addition, sequencing of the stool and sputum samples showed that the vitamin D 
insufficient group had different microbiota than the vitamin D sufficient group at the beginning of 
the study and that the vitamin D intervention changed the composition of the microbiota in both 
the gastrointestinal and respiratory tracts compared to placebo controls. Dr. Tangpricha 
concluded that vitamin D repletion favorably alters the microbiota in the lung and gut of cystic 
fibrosis patients.   
The second presentation reported on the effects of vitamin D status on microbially induced 
regulatory T cells in the mouse. The paper was presented by Juhi Arora  (Pennsylvania State 
University, USA), a graduate student in the Cantorna  laboratory. The effect of vitamin D on the 
microbiota included changes in several microbial species important for the induction of 
regulatory T cells such as Bacteroides, and Clostridium XIVa and Clostridium XVII clusters.  
Transplantation of the microbes from vitamin D sufficient and vitamin D deficient mice into the 
intestine of germfree mice phenocopied the higher numbers of regulatory T cells and protection 
from colitis seen in vitamin D sufficient versus vitamin D deficient recipient mice [20]. Together 
the two presentations establish that vitamin D status affects the composition of the microbiome 
in both humans and mice. The session further demonstrated a beneficial effect of vitamin D 
through the regulation of the microbiota in the mouse.  
The third talk from Dr. Stefan Tukaj (University of Gdansk, Poland) presented results 
showing that calcitriol treatment ameliorated the symptoms of a mouse model of epidermolysis 
bullosa acquisita (EBA), an anti-type VII collagen autoantibody-induced blistering skin disease. 
Calcitriol reduced immune effector cell activation and was associated with an increase in 
regulatory T and B cells as well as a reduction of pro-inflammatory T helper 17 cells in mice with 
immunization-induced EBA. These findings are significant because many patients with EBA 
present with vitamin D deficiency which suggest that vitamin D supplementation or treatment 
with analogues may be of therapeutic benefit. 
The next presentation of the session by Dr. Yanchun Li (University of Chicago, USA) 
reported on the effects of vitamin D and the vitamin D receptor on the development of type 3 
innate lymphoid cell (IL3C).   He noted that both VDR and Cyp27b1 gene deletion markedly 
reduced colonic ILC3 levels and that there were impaired responses to Citrobacter rodentium 
infection in both knockout lines.  The defects in IL3C in Cyp27b1 knockout mice could be 
restored by treatment with 1,25(OH)2 D and this regulation was independent of T lymphocytes, 
B lymphocytes, and the gut microbiota. The new data presented by Dr. Li established a role for 
vitamin D and 1,25(OH)2D in the  proliferation of the innate lymphoid cells, which was important 
for protection from gastrointestinal infection.  
Dr. Masako Suzuki (Albert Einstein College of Medicine, USA) reported on research that 
tested whether prenatal vitamin D deficiency causes long-term effects on postnatal immunity in 
mice. Offspring of vitamin D deficient or sufficient females were fed vitamin D sufficient diets. 
The investigators found that vitamin D deficiency during pregnancy reduced the proportion of T 
cells (CD4+ and CD8+) among CD45+ cells, whereas there was no significant difference in B 
cells between groups. They also found that the total number of bone marrow cells per body 
weight was significantly lower in offspring of vitamin D-deficient females. In addition, MPP4 
lymphoid progenitor and early-stage T cell progenitor cell populations were decreased by 
vitamin D deficiency during pregnancy. These results are important because vitamin D 
deficiency is common in reproductive-aged women and maternal vitamin D deficiency is strongly 
associated with immune-related conditions in offspring later in life. 
The session closed with a presentation by Grant Parnell (Westmead Institute, Australia) 
who assessed changes in immune cell expression of potentially vitamin D responsive multiple 
sclerosis (MS) risk genes. Supplementation altered the expression genes such as CYP24A1 in 
vitro in immune cells. However, in patients with clinically isolated syndrome (CIS), a precursor of 
MS, expression of these genes in whole blood was not altered upon supplementation with 25-
hydroxyvitamin D3 or given UV therapy. Notably, expression of marker genes, including 
CYP27B1, was lower in CIS than controls at baseline and expression of marker genes were 
correlated with each other, suggesting co-regulation. The researchers also found evidence of 
seasonal variation in marker gene expression, and correlation with serum 25D3 and solar UVB. 
The lack of response of marker gene expression to supplementation may have been due to 
insufficient activation of the 25-hydroxyvitamin D3 precursor due to limiting expression CYP27B1 
and/or insensitivity to supplementation due to homeostatic constraints.  
 
Session VIII  on Bone and mineral metabolism  was held in honor of Dr. Robert Wasserman, 
a leader in the field of vitamin D-regulated calcium binding proteins, who passed away in 2018.  
The session was chaired by Dr. Paul Anderson (University of South Australia, Australia) and 
Dr. Geert Carmeliet (KU Leuven, Belgium).  It was preceded by a tribute to Dr. Wasserman by 
Dr. Sylvia Christakos (Rutgers New Jersey Medical School, USA), who provided a thoughtful 
review of Dr. Wasserman’s contribution to our understanding of the mechanism of vitamin D-
mediated intestinal and renal calcium metabolism.  Dr. Wasserman’s research on the 
identification, induction by vitamin D, and function of the intestinal and renal calcium binding 
proteins (calbindin D9k and D28k in mammals, respectively) served as a foundation for the 
facilitated diffusion model of transepithelial calcium transport.   After her tribute, Dr. Christakos 
continued to give an invited talk that described new research on vitamin D signaling in the 
intestine [21]. He talk began with a review of her recent publication on the role of signaling 
through the VDR in the distal intestine.  This work showed that transgenic expression of VDR 
that is limited to the epithelial cells of the cecum and proximal colon is sufficient to recover the 
abnormal calcium and bone phenotype of global VDR knockout mice.  She then described 
research showing that there are large transcriptomic changes that occur in both the small 
intestine and colon following 1,25(OH)2D treatment.  In addition, she reported studies on human 
intestinal organoids to show that 1,25(OH)2D regulates more than 300 genes in organoids that 
model either the intestinal crypt or the differentiated cells in the intestinal villus. This expansion 
of the number of vitamin D regulated genes in the mouse and human intestine suggest that 
vitamin D regulates more intestinal biology than simply intestinal calcium absorption. Finally, 
explained that the high level of VDR expression that is typically seen in the intestine is 
dependent upon regulation mediated by the transcription factor Cdx-2. 
   In the second talk, Dr. Eva Liu (Brigham and Woman’s Hospital, USA) described her 
experiments on the role that 1,25(OH)2D plays in the development of enthesopathy, an 
abnormal mineralization of tendon attachment sites, in X-linked hypophosphatemia (XLH).  
Using the Hyp mouse model of XLH, she found that 1,25(OH)2D treatment or a blocking 
antibody to FGF23 both prevent expansion of hypertrophic enthesopathy cell expansion.  Next 
she showed that deletion of renal 1,25(OH)2D production in CYP27b1 knockout mice causes 
enthesopathy and other phenotypes of XLH.  Cell studies were presented that suggest 
1,25(OH)2D inhibits enthesopathy by suppressing BMP signaling in chondrogenic cells.  
  In the third presentation of the session, Stephanie Doms (KU Leuven, Belgium) reported 
research on a mouse model expressing a VDR that lacks the activation function 2 (AF2) domain 
(VDR∆AF2) and which is unresponsive to 1,25(OH)2D.  Initially, these mice looked similar to 
global VDR knockout mice with elevated serum PTH and 1,25(OH)2D and low bone mass.  
However, when directly compared to the VDR global knockout mice, VDR∆AF2 mice fed a high 
lactose, high calcium rescue diet have increased cortical porosity and a greater reduction in 
cortical thickness. These changes were not due to differences in the expression of intestinal or 
renal calcium transporter genes.  This suggests that there must be direct negative effects of 
unliganded VDR in bone cells.     
   The final presentation in the session was by Dr. Christopher Sempos (Vitamin D 
Standardization Program, USA).  In his talk, Dr. Sempos examined the role that serum 25OHD 
level plays in the prevention of rickets in Nigerian children.   Using a case-control approach, his 
group showed that serum 25OHD levels were significantly different in children with rickets but 
that these children and the control children have similar, low dietary calcium intakes (~ 200 
mg/d).   Additional analysis showed that serum 25OHD levels strongly discriminates between 
rickets and controls whereby children with levels < 40 nmol/L have a significantly higher odds of 
having rickets. 
 
Session IX , chaired by Dr. Moray Campbell (Ohio State University, USA) was on the 
interaction of Genetics and vitamin D biology .  The first talk in this session was an invited 
lecture by Dr. Brent Richards (McGill University, Canada) on the use of Mendelian 
Randomization (MR) as a tool to understand the role of vitamin D in disease.  Dr. Richards 
explained that because genetic variants are randomly assigned at conception, MR can use the 
natural genetic variation in genes controlling serum 25OHD levels to strengthen causal 
inference by mimicking a life-long randomized controlled trial (RCT).  The strengths of this 
approach is that it can be done in large populations of subjects, it decreases confounding, and it 
is not prone to reverse causation.   However, MR assumes that the relationship between serum 
25OHD and disease is linear, and this may not be true for all vitamin D-disease relationships.  In 
addition, MR is limited by the strength of the relationship between specific gene polymorphisms 
and serum 25OHD levels and it does not currently apply to genetic variation controlling either 
serum 1,25(OH)2D levels or action.  Thus, Dr. Richards explained that while MR is a population 
level approach that has features that improve upon the weaknesses of association studies and 
traditional RCT with vitamin D supplementation, it is not a perfect method and readers should 
appreciate these weaknesses when reading the MR literature. 
  The second talk in the session was by Dr. Folami Ideraabdullah (University of North Carolina 
at Chapel Hill, USA).  She discussed her recent studies on the epigenetic changes induced in 
offspring by maternal vitamin D deficiency that cause increases in male offspring bodyweight 
and adiposity.  New studies were described where by mice were fed a vitamin D deficient diet 
during a reciprocal mating strategy between two genetically divergent recombinant inbred 
mouse lines from the Collaborative Cross (CC001 and CC011); this allows genetically identical 
offspring to develop is distinct maternal and uterine environments.  She found that that both first 
and generation male offspring from the cross of female CC001 to male CC011 mice had higher 
bodyweight that was associated with reduced methylation of an imprinted gene in the liver.  She 
also found that male offspring from this cross had 2-3 more epimutations in the liver and sperm 
than the other cross.  This shows that despite identical dietary vitamin D intake, maternal 
genetic background can strongly influence the molecular and physiologic responses to vitamin 
D deficiency through epigenetic effects on the offspring. 
  The third talk of the session was presented by Dr. Amaud Molin (Caen University Hospital, 
France) on idiopathic infantile hypercalcemia (IIH).  He reported findings from a cohort of 8 IHH 
type 1 patients (7 children, 1 adult) that identified 13 variants in the SLC34A1 gene that encodes 
the renal phosphate transporter NaPi2A.  There were a variety of mutation types: 7 mis-sense 
mutations, 2 inframe deletions, and 3 splice site mutations, that all presented as precocious 
nephrocalcinosis.  Despite this, the spectrum of mutations caused both increases and 
reductions in serum phosphate.  Other family members of the subjects were found to have 
some phenotypes of IIH and one sister of an affected subject carried the same genotype as her 
sibling but had no IIH phenotype.  This suggests that other factors may affect the penetrance of 
the genetic effects on IIH. 
  The last presentation of the session was by Rikeenkumar Dhaduk (Loyola University, USA).  
He noted that serum 25OHD levels are lower among blacks than whites in the US and this led 
to the hypothesis that serum 25OHD levels are influenced by genetic factors in populations of 
African descent.  To test this hypothesis, a cohort of ~1600 African heritage subjects from 5 
countries were genotyped for 22 variants in 5 genes controlling vitamin D metabolism or action 
(GC, CYP2R1, CYP27B1, CYP24A1, VDR).  Variants in two genes, GC and CYP2R1, were 
significantly associated with serum 25OHD in the cohort, even after correcting for multiple 
comparisons.   
 
Session X  was a kenote lecture on The Year in Vitamin D: Clinical/Population Research by Dr. 
Inez Schoonmakers (University of East Anglia, Norwich, UK).  The session was chaired by Dr. 
Malachai McKenna (University College Dublin, Dublin, Ireland).  Dr. Schoonmakers noted that 
as of early 2019, around 3000 trials evaluating the effect of vitamin D as mono- or co-
intervention were registered, with a wide range of primary outcomes. Several of these are 
mega-trials with over 5000 participants and also collect data for a large number of secondary 
outcomes. Around 500 are currently in the stage of data collection. The majority of studies 
investigated adults, with only 653 of studies designed specifically to recruit children. Inspection 
of the world-wide distribution of trials shows that the fast-majority of RCTs are or were 
conducted in the US and EU. Relatively few are taking place in North Asia, South America and 
Africa, continents from which there are also few population-representative data are available on 
vitamin D status. Dr. Schoonmakers warned that the lack of data in these populations needs to 
be considered as the vitamin D research community interprets the emerging trial data in an 
international context.  Dr. Schoonmakers then went on to summarize the results from many of 
the most influential publications.  
Musculoskeletal. A meta-analysis and sequential analyses of vitamin D intervention trials (81 
trials with vitamin D mono-therapy or with calcium if the comparator groups also received 
calcium; total N= 53,537 adults over 18 years of age) reported non-significant effects of vitamin 
D on total fractures, hip fractures and falls, as well as small differences in lumbar spine and hip 
BMD but not at the femoral neck and total body [22]. However, the fast majority of included trials 
were conducted in populations with a mean baseline 25OHD > 50 nmol/L (43%) and the 
majority of trials lasted less than 1 year (i.e. a duration generally considered the minimum 
necessary to observe a change in BMD). These authors wrote a narrative review of subgroup 
analyses by baseline 25OHD, but they did not conduct a formal meta-analysis or Individual 
Patient Data meta-analysis. In response to this publication, several authors cautioned that the 
findings of this meta-analysis are not contradictory to earlier meta-analyses that showed a 
reduction in hip fracture risk in older people receiving vitamin D and calcium supplementation 
and they emphasized the importance of the vitamin D and calcium as co-therapies when taking 
anti-resorptive medication.  
   Several RCTs evaluated the effect of various dosages of vitamin D on muscle function and 
strength in healthy adults and older adults with or without frailty [23-27]. In contrast to 
observational studies that had showed negative muscle outcomes when vitamin D status was 
below 50 nmol/L or a meta-analyses of intervention studies that reported positive effects on 
muscle [28], the RCTs found no effects of supplementation on musculoskeletal endpoints. 
Cancer. Dr. Schoonmakers noted that there is strong evidence for an association between 
vitamin D status and cancer incidence from observational studies.  However, in the last year, 
two mega-trials reported vitamin D supplementation no effect on cancer incidence: VITAL, 2000 
IU D3/d  with or without  omega 3- fatty acids for 5.3 years [29]; ViDa: 100,000IU D3/m for 3.3. 
years [30]. However, the US-based VITAL trial did find a significant reduction in cancer mortality 
in the last 3.3 years of the trial. No interaction with baseline 25OHD (both as categorized by 
25OHD below or above 50 or 77.5 nmol/L) was found with any of the outcomes [29]. These data 
are consistent with other intervention trials on cancer incidence and mortality [31-36]. However, 
there was a significant interaction with BMI, with a protective effect of vitamin D 
supplementation on cancer incidence in those with a BMI <25 (HR 0.76).  This suggests that 
adiposity is an important modifier of vitamin D in canceer.  The results from several ongoing 
trails are anticipated in the next few years (D2dCa, D-Health and FIND [37, 38]), and these may 
provide additional insight on the interaction of body composition and vitamin D in cancer.   
Type 2 and gestational diabetes:   There is strong evidence for an association between vitamin 
D deficiency (serum 25OHD < 30 nmol/L) and increased risk of type 2 diabetes (T2D) from 
prospective cohort and observations studies. Two recent meta-analyses of intervention studies 
show small, but significant effects on glucose or insulin secretion and resistance in people with 
impaired glucose tolerance and vitamin D deficiency at baseline [39, 40]. In one of these, Li et 
al. [40] also showed a modifying effect of ethnicity (with effects particularly seen in Asian and 
Middle Eastern populations) and more pronounced effect of vitamin D status in patients with 
well-controlled T2D. Several recent, small RCTs conducted in overweight/obese or T2D patients 
also showed that vitamin D supplementation had benefits on glucose metabolism or insulin 
sensitivity with those these ethnic backgrounds [41-44]. In contrast, vitamin D supplementation 
was found to have no effect on markers of glycaemic control in an Individual Patient Data based 
re-analyses of data and samples of 12 RCTs in diverse European populations. Also, no 
interaction with baseline 25OHD was detected in a study that used Vitamin D Standardization 
Program-harmonised methodology [45].  Finally, in the DALI study [46] there was a small, 
significant effect of vitamin D supplementation on fasting glucose in pregnant women at 
increased risk of gestational diabetes whose baseline 25OHD was > 50 nmol/L.  However, 
vitamin D supplementation had no effect on insulin resistance or weight gain.  
Reproductive function and infant status. Conflicting data was reported from several studies that 
examined the association between maternal or paternal status and the effect of vitamin D 
supplementation on chances of conception, early and late pregnant losses, and stillbirth [47-53]. 
Strong evidence for a negative association between vitamin D status (predominantly at lower 
25OHD concentrations) and the risk of pregnancy complications is found in observational 
studies [54], but these were not confirmed in a meta-analysis of 43 intervention studies (N=8406 
subjects)[55]. In contrast, for several measures of fetal and infant development, there was 
consistency between the findings from meta-analyses of observational and intervention studies 
that related maternal vitamin D deficiency or insufficiency to vitamin D supplementation, e.g. risk 
of pre-term birth, birth anthropometrics, mental development and wheezing [55-58]. However, 
the positive effects of maternal supplementation on fetal and infant development were not 
replicated in a dose ranging placebo-controlled RCT conducted in Bangladesh, a population 
with a high risk of maternal vitamin D deficiency and foetal and infant growth restriction [59]. 
Interestingly, this study showed that at 3-months of age, the vitamin D status of an infant was no 
longer influenced by gestational maternal supplementation.  This shows that vitamin D stores 
are rapidly depleted during infancy and that while gestational vitamin D supplementation 
improves vitamin D status of term infants, additional vitamin D supplementation to the infant is 
required to maintain their status. A meta-analysis of the 25OHD response to vitamin D 
supplementation in infants (61 studies; total N=1828) estimated a required intake of 400 IU/d to 
maintain 25OHD ≥ 50 nmol/l in 97.5% of term infants [60].  
Secular trends in population vitamin D status: Recent publications from national surveys in the 
US and UK indicate that the population prevalence of deficiency (serum 25OHD <30 or 25 
nmol/L) has not decreased in recent years, although in the US the prevalence of inadequacy 
(serum 25OHD 30–49 nmol/L) did decline between 2003–2014 [61]. Disparities in vitamin D 
status and supplement use between ethnic groups and social-economic classes persist [62, 63]. 
Several professional societies have recently formulated position statements how to implement 
population recommendations and to prevent the burden of vitamin D deficiency in populations 
across the world [64-66]. 
   After presenting her view of the recently literature on vitamin D and health, Dr. Schoonmakers 
concluded that the latest research indicates that an effect of vitamin D supplementation is 
mostly limited to those with low vitamin D status at baseline and/or at increased disease risk. 
She noted that several, current ongoing RCTs specifically recruit participants with vitamin D 
deficiency and that the field of vitamin D is anxiously awaiting the results of studies to determine 
if they confirm these findings. Dr. Schoonmaker also noted that recent findings also suggest that 
there are potential ethnic differences in the effect of vitamin D supplementation on outcomes. 
This may be related to differences in vitamin D status and disease risk between populations. 
Emerging research in different continents will address these population differences.  
 
A session on vitamin D and Public Health (Session XI) was chaired by Dr. Susan Whiting, 
(University of Saskatchewan, Saskatoon, Canada).  This session began with an invited lecture 
by Dr. Stephanie Atkinson (McMaster University, Hamilton, Canada).   She summarized the 
rationale for, and process that led to, the vitamin D intake guidelines for persons affected by 
multiple sclerosis (MS) that was released by the MS Society of Canada in November 2018 
https://mssociety.ca/library/document/Vka6RXcnOizNm9sIwuWvroxejlhLqTJ8/original.pdf [67].   
These guidelines were developed by an expert panel over a period of 18 months.  She noted 
that although there was consistent and growing evidence for a causal link between MS risk and 
vitamin D status, there was a paucity of type of research needed to definitively define specific 
intake levels for health-related recommendations.  As such, the guidelines for people at risk for 
MS, as well as for people living with MS, are similar to those for the public.  In addition, Dr. 
Atkinson noted that the panel made a clear statement that vitamin D should not be used as a 
stand-alone treatment for MS.  
   The second talk of the session on food vehicles for vitamin D fortification was by Dr. Kevin 
Cashman (University College Cork, Ireland).  His research group identified 7 low-middle income 
countries that have a high prevalence of vitamin D deficiency and who might benefit from a 
vitamin D food fortification program.  They then modeled the potential impact that fortifying three 
different food vehicles (edible oil, wheat or maize flour, and milk) could have on mean vitamin D 
intake in all 7 of the countries.  By using usual intakes of these foods in the 7 countries, they 
calculated the levels of fortification that could significantly increase vitamin D intake.  Their data 
also demonstrated how different food vehicles need to be considered in the different countries 
to improve vitamin D intake. 
 
Session XXII  on New Functions of Vitamin D  war chaired by Dr Reinhold G. Erben 
(University of Veterinary Medicine Vienna). The session was opened by Dr Jacob Rullo 
(Queen’s University Ontario) who presented a study in 120 patients undergoing ophthalmic 
procedures, in which 25OHD concentrations were measured in blood and in the eye, together 
with ocular expression of CYP27B1, CYP24A1, and VEGF. 25OHD was clearly detected in the 
eye at varying and disease-dependent concentrations, together with the enzymes responsible 
for production and inactivation of the vitamin D hormone. He suggested that vitamin D 
production and signaling in the eye may be important for maintenance of the visual machinery 
and in ocular disease pathogenesis. Next, Dr Erica Mandell (University of Colorado) reported 
the results from a rat study aimed at testing the role of maternal vitamin D deficiency on fetal 
lung development. Newborn pups from vitamin D deficient mothers showed reduced pulmonary 
vessel density and reduced radial alveolar counts. In addition, pulmonary endothelial cells 
cultured from these pups had reduced cell growth and tube formation. She speculated that 
maternal vitamin D deficiency may hamper normal lung development in the fetus, predisposing 
the offspring to respiratory disease later in life. Finally, Dr Nejla Latic (University of Veterinary 
Medicine Vienna) reported on a study in male cardiomyocyte-specific VDR knock-out mice that 
were subjected to transverse aortic constriction as an afterload-induced left ventricular 
hypertrophy model. The sham-operated cardiomyocyte-specific VDR knockout mice had normal 
mineral homeostasis, and did not show cardiac hypertrophy or a cardiovascular phenotype. 
However, echocardiography revealed that compared with VDR floxed control mice, 
cardiomyocyte-specific VDR knockout mice had left ventricular functional impairment after 
transverse aortic constriction. The findings indicate that vitamin D signaling is dispensable in the 
heart under normal conditions, but that vitamin D signaling in cardiomyocytes has a protective 
function in the stressed heart. 
 
Session XIII  was the last scientific session of the meeting and it explored the controversy 
surrounding vitamin D requirements during pregnancy .  The session was chaired and 
moderated by Dr. Mairead Kiely (University College Cork, Cork, Ireland) and included the 
participation of two discussants: Dr. Daniel Roth (The Hospital for Sick Children, Toronto, 
Canada) and Dr. Carol Wagner (Medical University of South Carolina, USA).  Initially, Dr. Kiely 
explained the motivation for the session by noting that research on vitamin D and pregnancy is 
a neglected area.  This is true despite the fact that low vitamin D status is common in pregnant 
women and that the evidence available for setting the vitamin D requirement during the 2011 
US Dietary Reference Intakes (DRI) deliberations was weak [68].  She also noted that trials on 
vitamin D and pregnancy are often designed to test the benefit of additional vitamin D rather 
than to answer the question “What level of vitamin D status or intake is sufficient to support a 
healthy pregnancy?”    During a series of presentations by Drs. Roth and Wagner, and in an 
extended discussion that followed, the current state of the evidence based on considerations of 
vitamin D metabolism in pregnancy and the prevalence of gestational vitamin D deficiency 
worldwide was evaluated.  The panel went on to discuss the challenge of translating laboratory 
research findings on the role of vitamin D in perinatal health to clinical studies; the challenges of 
designing and conducting clinical trials to establish prenatal vitamin D requirements; and results 
to date of major large randomized controlled trials of prenatal vitamin D supplementation. During 
the discussion, the speakers and audience also explored potential next steps towards 
generating robust clinical data in this field that would address both public health protection and 
patient care. Overall, there was a plurality of divergent viewpoints represented rather than a 
unified or consensus position by the speakers or the audience. 
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